Skip to content
entacapone

Structure via PubChem · Public domain (PubChem)

EntityQ416444· pop 23· linked from 266 articles

entacapone

Sign in to save

Also known as COM998, OR-611, (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide, N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide

Entacapone, sold under the brand name Comtan among others, is a medication commonly used in combination with other medications for the treatment of Parkinson's disease. Entacapone together with levodopa and carbidopa allows levodopa to have a longer effect in the brain and reduces Parkinson's disease signs and symptoms for a greater length of time than levodopa and carbidopa therapy alone.

Chemical data

Formula
C14H15N3O5
Molecular weight
305.29 g/mol
IUPAC name
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
SMILES
CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N
InChIKey
JRURYQJSLYLRLN-BJMVGYQFSA-N
XLogP
2.1
Polar surface area
130 Ų
H-bond donors
2
H-bond acceptors
6
Formal charge
0

via PubChem

Research

865 papers

via PubMed

Wikidata facts

Mass
305.101171
Show 6 more facts
chemical formula
C₁₄H₁₅N₃O₅
Commons category
Entacapone
defined daily dose
1
canonical SMILES
CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N
isomeric SMILES
CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N
World Health Organisation international non-proprietary name
entacapone
Sources (9)

via Wikidata · CC0

~8 min read

Article

23 sections
Contents
  • Medical uses
  • Pregnancy and breastfeeding
  • Children
  • Liver problems
  • Kidney problems
  • Contraindications
  • Side effects
  • Movement problems
  • Diarrhea
  • Urine color
  • Sudden sleep onset
  • Low blood pressure
  • Behavior problems
  • Interactions
  • Pharmacology
  • Mechanism of action
  • Pharmacokinetics
  • Absorption
  • Distribution
  • Metabolism and elimination
  • Research
  • Restless legs syndrome
  • References

Entacapone, sold under the brand name Comtan among others, is a medication commonly used in combination with other medications for the treatment of Parkinson's disease. Entacapone together with levodopa and carbidopa allows levodopa to have a longer effect in the brain and reduces Parkinson's disease signs and symptoms for a greater length of time than levodopa and carbidopa therapy alone.

Entacapone is a selective and reversible inhibitor of the enzyme catechol-O-methyltransferase (COMT). When taken together with levodopa (L-DOPA) and carbidopa, entacapone stops COMT from breaking down levodopa, resulting in an overall increase of levodopa remaining in the brain and body. Entacapone does not cross into the brain and hence does not inhibit COMT there.

Connections

Categories